A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2018
At a glance
- Drugs Palbociclib (Primary) ; Fulvestrant; Letrozole
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PARSIFAL; PARSIFAL I
- 12 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jan 2019.
- 12 Jan 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2019.
- 12 Jan 2018 Status changed from recruiting to active, no longer recruiting.